EirGenix, Inc products
Product Pipeline
EirGenix - Model EG12014/EGI014 - Trastuzumab Biosimilar
Product: EG12014/EGI014 Trastuzumab Biosimilar. Indication: Cancer. Target: HER2. Status: BLA.
EirGenix - Model EG1206A - Pertuzumab Biosimilar
Product: EG1206A Pertuzumab Biosimilar. Indication: Cancer. Target: HER2. Status: Phase I.
EirGenix - Model EG13074 - High Quality Biologic Products
Product: New Formulation. Indication: Cancer. Target: HER2. Status: Preclinical.
EirGenix - Model TSY0110 (EG12043) - Antibody-Drug Conjugate
Product: TSY0110 (EG12043) Antibody-Drug Conjugate. Indication: Cancer. Target: HER2. Status: Preclinical.
EirGenix - Model EG12021 - Bevacizumab Biosimilar
Product: EG12021 Bevacizumab Biosimilar. Indication: Cancer. Target: VEGF. Status: Preclinical.
EirGenix - Model EG74032 - CRM197 Carrier Protein
Product: EG74032 CRM197 Carrier Protein. Target: Carrier protein for conjugate vaccines. Status: GMP manufacturing.
EirGenix - Model EG62054 - Biosimilar
Product: EG62054 Biosimilar. Indication: Undisclosed. Target: Undisclosed. Status: Preclinical.
Others
Model CRM197 - Non-Toxic Mutant of Diphtheria Toxin
CRM197 (Cross Reacting Material 197) is a non-toxic mutant of diphtheria toxin (58 Kd). CRM197 has been tested in animals studies and it has been demonstrated to lack toxicity. CRM197 can be used as a carrier protein for vaccine delivery. It acts by helping polysaccharide antigens to bind on and be internalized into antigen-presenting cells. This in turn induces T-cell-dependent responses.
Covid-19 Antigen Rapid Test
It can detect COVID-19 and get result in 10 minute!